• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target

    1/12/23 7:54:45 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORMP alert in real time by email
    Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously
    Get the next $ORMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORMP

    DatePrice TargetRatingAnalyst
    1/12/2023$30.00 → $3.00Buy → Hold
    Canaccord Genuity
    2/18/2022$20.00Overweight
    Cantor Fitzgerald
    11/30/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/29/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/2/2021$20.00 → $35.00Buy
    Aegis Capital
    7/29/2021$27.00 → $30.00Buy
    Canaccord Genuity
    More analyst ratings

    $ORMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mayer Arie was granted 36,975 shares, increasing direct ownership by 38% to 133,109 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      6/9/25 4:08:35 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Aghion Daniel was granted 38,371 shares, increasing direct ownership by 99% to 77,191 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      6/9/25 4:08:22 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Reznick Yehuda was granted 38,370 shares, increasing direct ownership by 126% to 68,930 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      6/9/25 4:08:06 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously

      1/12/23 7:54:45 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      2/18/22 6:43:35 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Oramed Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously

      11/30/21 7:36:11 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care